2022_cardiac_webinar
Role of Diagnostics in heart failure

In Australia, coronary heart disease holds the unfortunate title of being Australia's leading cause of death. (Reference 1) 

Together with the loss of health and life, cardiovascular diseases as a whole were estimated at to cost of 9.1% of total allocated expenditure in the Australian health system (2019–20, $12.7 billion), the second highest expendature behind musculoskeletal disorders ($14.6 billion). (Reference 2)

Diagnostics are integral to early identification and treatement of disease. There have been major advances in our management of heart failure (HF) such that compared to ten years ago, modern therapy can reduce heart failure death and cardiovascular mortality by up to 60% in a patient diagnosed at age 50. (References 3,4)

NT-ProBNP use in cardiology

The cardiac biomarker NT-proBNP offers significant diagnostic value when assessing cardiac patients, particularly those with comorbidities such as diabetes and congenital heart disease. 

To help with the diagnostic educational program and enable Australian clinicians, three of Australias leading experts on Heart failure - Professor Andrew Sindone, A/ Prof. Christine Burdeniuk and Professor Jonathan Shaw, contributed to the 2022 webinar entitled the "Role of NT-proBNP in Management of Heart Failure".

Sample of the wbinar recording
View the full webinar recording

Click here to view the full recording of the webinar, which can be viewed on the Cardio ThinkLab website - "Role of Diagnostics: NT-proBNP in management of Heart Failure". 

Professor Andrew Sindone presented on the "Latest Advances in Heart Failure Management in Australia". Speaking to the role of biomarkers and the STRONG-HF trial, Prof. Sindone outined some of the current challenges in heart failure management in Australia, as well as cross-country collaborations. Prof. Sindone is Director, Heart Failure Unit, Concord Hospital and Head of Department of Cardiology, Ryde Hospital, NSW.

Associate Professor Christine Burdeniuk presented on "Early NT-proBNP testing in Acute and Chronic Heart Failure" covering the value of biomarkers for patients suspected of acute heart failure (HF) in HFpEF, and the effects of angiotensin receptor–neprilysin inhibitor ARNi in patients of HFpEF. Also covered were the discharge management and post discharge management of such patients. A/ Prof. Christine Burdeniuk's associations include Flinders University, and SALHN (South Adelaide Local Health Network)

To complete the webinar, Professor Jonathan Shaw presented on "the Potential Role of NT-proBNP as a Predictor of Future Risk of Heart Failure in Type 2 Diabetes Mellitus Patients". Topics included the current challenges and unmet needs with respect to cardiovascular assessment in type 2 diabetes mellitus (T2DM) patients, the role of SGLT2 inhibitor in preventing heart failure and current challenges in implementation of the guidelines in such patients. Professor Jonathan Shaw is Deputy Director (Clinical and Population Health) at the Baker Heart and Diabetes Institute, Melbourne.

There is immense diagnostic potential for measuring such subtle yet distinct changes in the body. Biomarkers can often capture what is happening in a cell or an organism at a given moment, In other words they are an early warning system for a patient's health.Roche has been the pioneer in cardiac biomarkers for over 30 years. 

In our capacity as a diagnostic leader, Roche Diagnostics Australia is committed to reducing the burden of disease caused by CVD, and providing better outcomes for everyone in Australia.

 

 

Reference 1 - https://www.heartfoundation.org.au/bundles/for-professionals/coronary-heart-disease-key-stats (last accessed 3/7/23)

Reference 2 - https://www.aihw.gov.au/reports/heart-stroke-vascular-diseases/hsvd-facts/contents/impacts/expenditure-on-cardiovascular-disease (last accessed 3/7/23)

Reference 3 - Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet 2020;396(10244):121-128. (In eng). DOI: 10.1016/s0140-6736(20)30748-0.

Reference 4 - Tromp J, Ouwerkerk W, van Veldhuisen DJ, et al. A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. JACC Heart Fail 2022;10(2):73-84. (In eng). DOI: 10.1016/j.jchf.2021.09.004.